Immunotherapy using anti‐PD‐1/PD‐L1 antibodies for several types of cancer has received
considerable attention in recent decades. However, the molecular mechanism underlying …

Large-scale genomic profiling of pancreatic cancer (PDAC) has revealed two distinct
subtypes:'classical'and 'basal-like'. Their variable coexistence within the stromal immune …

The NLRP3 inflammasome has been implicated in the pathogenesis of a wide variety of
human diseases. A few compounds have been developed to inhibit NLRP3 inflammasome …

Although checkpoint immunotherapies have revolutionized the treatment of cancer, not all
tumor types have seen substantial benefit. Pancreatic ductal adenocarcinoma (PDAC) is a …

Background Pancreatic cancer (PC) is a common malignancy of the digestive system and is
characterized by poor prognosis and early metastasis. Tumor immune escape plays an …

Background & Aims We have shown that reciprocally activated rat sarcoma (RAS)/mitogen-
activated protein kinase/extracellular signal-regulated kinase (MEK) and Janus …

Tumor-associated macrophages (TAMs) are abundant in pancreatic ductal
adenocarcinomas (PDACs). While TAMs are known to proliferate in cancer tissues, the …

Co-occurrent KRAS and TP53 mutations define a majority of patients with pancreatic ductal
adenocarcinoma (PDAC) and define its pro-metastatic proclivity. Here, we demonstrate that …

Inflammation and immunity are important determinants of cancer initiation, promotion, and
progression to cancer equilibrium or suppression. The NOD-like receptor family pyrin …

The NLRP3 inflammasome acts as a danger signal sensor that triggers and coordinates the
inflammatory response upon infectious insults or tissue injury and damage. However, the …